The turn of the year saw the end of 84 years’ ownership by Novo Nordisk A/S, when Steno Diabetes Center (SDC) was transferred to the Capital Region of Denmark. Steno became part of a completely new visionary venture; Steno Diabetes Center Copenhagen (SDCC).
The ambition for the new centre is to raise the bar for the entire diabetes field in the Capital Region of Denmark and to contribute inspiration and new knowledge at national and international levels. This will be through offering the best treatment and prevention for everyone in the region with diabetes. The new director of the centre, Prof. Allan Flyvbjerg has now rolled up his sleeves and is ardently laying plans for the first steps.
“Everyone in the region with diabetes should be offered the same high-quality treatment, irrespective of whether they are being monitored by a diabetes department, a health centre or their GP,” he said, and added:
“Therefore we’ll be setting up partnerships with other hospitals, general practice, municipalities, universities and other educational institutions in the regions, whereby we can collaborate on increasing focus on diabetes and improve treatment”.
SDCC was established following a donation of DKK 2.945 billion (€396 million) from the Novo Nordisk Foundation, which, in addition to the many joint activities in the region, will also make it possible to build a new diabetes centre at which up to 14,000 people with diabetes can receive treatment. Construction of the new centre next to Herlev-Gentofte Hospital in Herlev will be completed at the end of 2020 and Tean Cowi A/S will be the main contractors. Treatment will continue at Niels Steensens Vej in Gentofte until the new centre is finished.